Patient-reported outcomes for multicentric Castleman's disease in a randomized, placebo-controlled study of Siltuximab.
van Rhee, F Rothman, M Ho, K Fleming, S Wong, R Fosså, A Dispenzieri, A Cavet, James Munshi, N Vermeulen, J
van Rhee, F
Rothman, M
Ho, K
Fleming, S
Wong, R
Fosså, A
Dispenzieri, A
Cavet, James
Munshi, N
Vermeulen, J
Citations
Altmetric:
Abstract
Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently shown to be effective in a registration clinical trial. MCD symptoms, such as fatigue, pain, and weakness, are most appropriately quantified using patient-reported outcome (PRO) measures. We assessed the effect of siltuximab on patient perception of symptoms, functional status, and wellbeing using PRO instruments.
Description
Date
2015
Publisher
Collections
Keywords
Type
Article
Citation
Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. 2015, 8 (2):207-16 Patient